Information Provided By:
Fly News Breaks for January 3, 2019
NVAX
Jan 3, 2019 | 19:37 EDT
Piper Jaffray analyst Edward Tenthoff raised his price target on Novavax to $4.50 and kept his Overweight rating after its positive top-line Phase II immunogenicity data on quadrivalent NanoFlu vaccine. The analyst intends to await Phase III PREPARE top-line data on ResVax this quarter, he sees potentially positioning the company to file for approval of the drug with the FDA and EMA in 2020.
News For NVAX From the Last 2 Days
There are no results for your query NVAX